In the article Flocoumafen we will explore different aspects related to this topic, from its origins to its relevance today. We will analyze how Flocoumafen has impacted society and how it has evolved over time. Additionally, we will examine the different perspectives and opinions that exist around Flocoumafen, providing a complete and balanced overview of this topic. Throughout the article, we will delve into specific aspects that will help understand the importance and impact of Flocoumafen in various areas. Through a critical and reflective approach, we aim to offer our readers a complete and enriching vision of Flocoumafen.
Names | |
---|---|
IUPAC name
2-Hydroxy-3-methoxy)phenyl]-1,2,3,4-tetrahydronaphthalen-1-yl] chromen-4-one
| |
Identifiers | |
3D model (JSmol)
|
|
ECHA InfoCard | 100.102.053 |
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C33H25F3O4 | |
Molar mass | 542.554 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
|
Flocoumafen is a fluorinated, second-generation anticoagulant of the 4-hydroxycoumarin vitamin K antagonist type. It is a second generation (i.e., high potency) chemical in this class, used commercially as a rodenticide. It has a very high toxicity and is restricted to indoor use and sewers (in the UK). This restriction is mainly due to the increased risk to non-target species, especially due to its tendency to bio-accumulate in exposed organisms. Studies have shown that rodents resistant to first-generation anticoagulants can be adequately controlled with flocoumafen. It was synthesized in 1984 by Shell International Chemical.
In most rodents, the LD50 is 1 mg/kg, but it can vary between species: from 0.12 mg/kg in the common vole (Microtus arvalis) to more than 10 mg/kg in the Cairo spiny mouse (Acomys cahirinus). For dogs the LD50 is 0.075-0.25 mg/kg.
The antidote to flocoumafen is vitamin K1, which must be administered over a period of several weeks or even months.